AzTrials
AzTrials

Ulcerative ColitisPhase 2NCT05177835

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

A Phase 2 study testing ABX464 in people with Ulcerative Colitis, run by Abivax S.A. at 46 sites in 14 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ulcerative Colitis
What is being tested?
ABX464
Could I receive a placebo?
No, everyone receives an active treatment
How many people
203 participants
Where
46 sitesin 14 countries
Study dates
3 Dec 2021to Apr 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies
  • Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of ≤1 ;
  • Subjects able and willing to comply with study visits and procedures;
  • Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures;
  • 5. Women of childbearing potential and men receiving the study treatment and their partners must agree to continue a highly effective contraceptive method during the study and for 6 months (180 days) after end of study or early termination. Women must be surgically sterile or if of childbearing potential must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include true abstinence, intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation, intrauterine hormone releasing system, bilateral tubal ligation, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle. Female and male subjects must not be planning pregnancy during the trial and for 6 months post completion of their participation in the trial. In addition, male subjects should use condom during the trial and for 6 months (180 days) post completion of their participation in the study. Male subjects must not donate sperm as long as contraception is required. For the purpose of this protocol, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. Finally, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy;
  • Subjects should be affiliated to a social security regimen (for French sites only).

Who cannot join

  • Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study
  • Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  • Subjects who are participating or plan to participate in other investigational studies (other than induction study) during the study.

Trial locations and contacts

46 sites in 14 countries.

46 sites in 14 countries

Poland13 sites
  • Centrum Medyczne Plejady

    Krakow

  • Samodzielny PZOZ w Lecznej

    Łęczna, 21-010

  • Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj sp. p

    Lublin

  • Wojskowy Szpital Kliniczny w Lublinie

    Lublin

  • Medicome Sp. z o. o.

    Oświęcim

  • Trialmed CRS

    Piotrkow Trybunalski

  • Termedia Sp. z o.o (NSZOZ Termedica - Centrum Badan Klinicznych)

    Poznan

  • Ośrodek Badań Klinicznych "METABOLICA"

    Tarnów

  • Medical Network Sp. z o.o.

    Warsaw

  • Santa Sp. z o.o.

    Warsaw

  • Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska

    Wroclaw

  • Centrum Medyczne Oporow

    Wroclaw

  • LexMedica

    Wroclaw

Other trials in Poland

France5 sites
  • Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble

  • Centre Hospitalier Universitaire De Montpellier

    Montpellier

  • CHU Nantes - Hôtel Dieu

    Nantes

  • Institut des MICI

    Neuilly-sur-Seine

  • CHU Saint Etienne - Hôpital Nord

    Saint-Etienne

Other trials in France

Hungary4 sites
  • DRC Gyogyszervizsgalo Kozpont Kft.

    Balatonfüred

  • Semmelweis University

    Budapest

  • Vasutegeszseguegyi Nonprofit Koezhasznu Kft.

    Debrecen

  • Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház I. Belgyógyászat

    Győr

Other trials in Hungary

Germany3 sites
  • Goethe University Frankfurt

    Frankfurt

  • Studiengesellschaft BSF UG (haftungsbeschraenkt)

    Halle

  • Medizinische Hochschule Hannover

    Hanover

Other trials in Germany

Italy3 sites
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma

  • Humanitas Mirasole S.p.A.

    Rozzano

  • IRCCS Ospedale Sacro Cuore Don Calabria

    Verona

Other trials in Italy

Slovakia3 sites
  • Cliniq s.r.o.

    Bratislava

  • GASTRO I, s.r.o.

    Prešov

  • Endomed s.r.o

    Vranov nad Topľou

Other trials in Slovakia

Slovenia3 sites
  • Splošna bolnišnica Celje

    Celje

  • Univerzitetni klinični center Maribor

    Maribor

  • Splosna Bolnisnica Murska Sobota

    Murska Sobota

Other trials in Slovenia

Austria2 sites
  • Medizinische Universitaet Innsbruck

    Innsbruck

  • Medical University of Vienna

    Vienna

Other trials in Austria

Belgium2 sites
  • Antwerp University Hospital

    Antwerp

  • UZ Leuven

    Leuven

Other trials in Belgium

Czechia2 sites
  • Fakultni nemocnice u sv. Anny v Brne

    Brno

  • Nemocnice Slany

    Slaný

Other trials in Czechia

Serbia2 sites
  • Kliničko bolnički centar Zvezdara

    Belgrade

  • Opšta bolnica "Đorđe Joanović" Zrenjanin Odsek za gastroenterologiju

    Zrenjanin

Other trials in Serbia

Ukraine2 sites
  • Communal non-commercial enterprise "Cherkasy Regional Hospital of Cherkasy regional council"

    Cherkasy

  • Communal non-commercial enterprise "Khmelnytska Regional Hospital" of Khmelnytskiy regional council

    Khmelnytskyi

Other trials in Ukraine

Canada1 site
  • South Edmonton Gastroenterology

    Edmonton

Other trials in Canada

Spain1 site
  • Centro Medico Teknon

    Barcelona

Other trials in Spain

About this study

Official title: A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment.

All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement.

Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.

Being tested
ABX464
Keywords
Moderate to severe ulcerative colitis
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ABX464Drug

    All subjects will receive ABX464 given at 25 mg QD.

Study groups in NCT05177835
Study groupRoleWhat they receive
ABX464 -25mgExperimentalAll subjects will receive ABX464 given at 25 mg QD.
Receives: Drug: ABX464

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of adverse events in ABX464 treated subjects

    To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.

    Measured: From Baseline to a maximum period of 78 months

Secondary outcomes (4)
  1. Percentage of subjects reaching clinical remission at yearly visits.

    To evaluate the long-term effect of ABX464 on clinical remission

    Measured: From Baseline to a maximum period of 78 months

  2. Percentage of subjects reaching endoscopic remission at yearly visits

    To evaluate the long-term effect of ABX464 on endoscopic remission

    Measured: From Baseline to a maximum period of 78 months

  3. Percentage of subjects reaching clinical response at yearly visits

    To evaluate the long-term effect of ABX464 on clinical response

    Measured: From Baseline to a maximum period of 78 months

  4. Percentage of subjects reaching endoscopic improvement at yearly visits

    To evaluate the long-term effect of ABX464 on endoscopic improvement

    Measured: From Baseline to a maximum period of 78 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2022
  2. Study start3 Dec 2021
  3. Primary completionMar 2028 (estimated)
  4. Study completionApr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Open Label Follow-up Study
Masking
None (open label)
Enrolment
203 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05177835
Sponsor's protocol ID
ABX464-108
Status last verified
Apr 2026
First submitted
15 Dec 2021
Last updated
27 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ABX464 in people with Ulcerative Colitis, run by Abivax S.A. at 46 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 46 sites in Poland, France, Hungary, Germany, Italy and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of adverse events in ABX464 treated subjects (time frame: From Baseline to a maximum period of 78 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in